Prostate Cancer Discovery and Development Program, Philadelphia, PA, USA.
Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, 19104, USA.
Oncogene. 2019 Oct;38(43):6926-6939. doi: 10.1038/s41388-019-0939-7. Epub 2019 Aug 12.
Tumor mitochondria have heightened protein folding quality control, but the regulators of this process and how they impact cancer traits are not completely understood. Here we show that the ATP-directed mitochondrial protease, LonP1 is upregulated by stress conditions, including hypoxia, in tumor, but not normal cells. In mitochondria, LonP1 is phosphorylated by Akt on Ser173 and Ser181, enhancing its protease activity. Interference with this pathway induces accumulation of misfolded subunits of electron transport chain complex II and complex V, resulting in impaired oxidative bioenergetics and heightened ROS production. Functionally, this suppresses mitochondrial trafficking to the cortical cytoskeleton, shuts off tumor cell migration and invasion, and inhibits primary and metastatic tumor growth, in vivo. These data identify LonP1 as a key effector of mitochondrial reprogramming in cancer and potential therapeutic target.
肿瘤线粒体具有更高的蛋白质折叠质量控制,但该过程的调节因子及其对癌症特征的影响尚不完全清楚。在这里,我们表明,ATP 导向的线粒体蛋白酶 LonP1 受到应激条件(包括缺氧)的上调,这种上调仅发生在肿瘤细胞中,而不是正常细胞中。在线粒体中,LonP1 被 Akt 在 Ser173 和 Ser181 上磷酸化,从而增强其蛋白酶活性。干扰这条通路会导致电子传递链复合物 II 和复合物 V 的错误折叠亚基积累,导致氧化生物能受损和 ROS 产生增加。从功能上讲,这会抑制线粒体向皮质细胞骨架的运输,关闭肿瘤细胞的迁移和侵袭,并抑制体内原发性和转移性肿瘤的生长。这些数据表明 LonP1 是癌症中线粒体重编程的关键效应因子,也是潜在的治疗靶点。